Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...

Benjamin Hill travels the nation collecting stories about what makes Minor League Baseball unique. This excerpt from his ...

South Korean gaming giant Krafton is partnering with one of its investee companies, the audio content platform Kuku FM, to ...

Create rich, interactive reports with visual analytics at your fingertips—for free. Dig deeper into data and find patterns you may have otherwise missed that lead to actionable insights. Use features ...

Download Google Chrome for PC to use an essential tool on the Internet. The favorite browser for over a billion users. Every year its market share goes rocket high, and that's despite being the latest ...